Charcot-Marie-Tooth disease type 1A is a genetic nerve condition that affects the legs, feet, and hands. People with Charcot-Marie-Tooth disease type 1A often notice foot drop, ankle weakness, frequent tripping, and numbness or tingling. It usually starts in childhood or the teen years and tends to progress slowly over life. Most people with Charcot-Marie-Tooth disease type 1A have a normal life span, but daily activities can be affected. Treatment focuses on supportive care like physical and occupational therapy, ankle–foot orthoses, pain control, and sometimes surgery for foot deformities.
Overview
Charcot-marie-tooth disease type 1aSymptoms
Charcot-Marie-Tooth disease type 1A causes slowly worsening weakness in the lower legs and feet, leading to tripping, ankle sprains, and foot drop. Numbness, tingling, poor balance, high arches, cramps, and later hand weakness often begin in childhood or adolescence.
Outlook and prognosis
Many living with Charcot-Marie-Tooth disease type 1A (CMT1A) have a slowly progressive course, often staying active for decades. Symptoms tend to start in childhood or teens and gradually advance, with life expectancy typically near typical ranges. Early therapy, bracing, and fall‑prevention help preserve mobility and independence.
Causes and risk factors
CMT1A results from a duplication of the PMP22 gene, most often inherited from an affected parent; new changes can arise spontaneously. Risk rises with family history. Diabetes, heavy alcohol use, certain nerve‑toxic medicines (for example, vincristine) can worsen severity.
Genetic influences
Genetics are central in Charcot‑Marie‑Tooth disease type 1A. Most cases result from a PMP22 gene duplication, inherited in an autosomal dominant pattern, though new (de novo) changes occur. Variations can influence age at onset, symptom severity, and progression.
Diagnosis
Doctors review walking and hand-strength changes, family history, and exam findings, then order nerve conduction studies. Genetic diagnosis of Charcot-Marie-Tooth disease type 1A is confirmed by a PMP22 duplication test.
Treatment and drugs
Treatment for Charcot-Marie-Tooth disease type 1A focuses on maintaining strength, balance, and independence. Many benefit from tailored physical and occupational therapy, ankle–foot orthoses, supportive footwear, pain management, and sometimes surgery for severe foot deformities. Regular follow-up, fall prevention, and genetic counseling help guide long-term care.
Symptoms
Many living with Charcot-Marie-Tooth disease type 1A (CMT1A) notice changes in foot strength and balance that make walking longer distances or uneven ground more tiring. Early features of Charcot-Marie-Tooth disease type 1A often include frequent tripping, ankle rolling, or trouble with buttons due to hand weakness. Features vary from person to person and can change over time.
Weakness starts in the small muscles of the feet and ankles, making it harder to push off or climb stairs. Shoes may feel less secure because the muscles do not hold the foot as firmly.
Lifting the front of the foot is difficult, leading to a slapping step or tripping. People often pick their knees up higher to clear the ground.
High arches and curled toes are common structural changes in CMT1A. They can make shoe fit tricky and increase pressure points that lead to calluses.
Reduced feeling in the feet and ankle weakness can make balance unsteady, especially in the dark or on uneven surfaces. This raises the risk of slips and falls.
How people usually first notice Charcot-marie-tooth disease type 1a?
Many people first notice Charcot-Marie-Tooth disease type 1A when childhood milestones feel a bit out of sync, like frequent tripping, clumsiness in gym class, or ankles that roll easily because the muscles in the lower legs are weaker and tire quickly. Parents or teachers may spot high arches, hammertoes, or a “steppage” gait, and later a doctor may confirm decreased ankle reflexes and reduced vibration sense; these are common first signs of CMT1A. Sometimes it’s first recognized after a minor injury lingers or during a family check-up when others have similar foot shape or walking patterns, prompting evaluation and genetic testing.
Types of Charcot-marie-tooth disease type 1a
Charcot-Marie-Tooth disease type 1A (CMT1A) has a fairly consistent pattern—slowly progressive weakness and wasting in the lower legs and feet first, then often the hands—but symptoms can vary in when they start and how strongly they show up. People may notice different sets of symptoms depending on their situation. Clinicians often describe them in these categories: sensory changes, motor weakness, foot deformities, hand involvement, and balance or fatigue issues. Below are the main types of symptoms people with CMT1A tend to experience and how they differ, which can help you recognize early symptoms of Charcot-Marie-Tooth disease type 1A in everyday life.
Foot and ankle
Weakness in the lower legs leads to ankle rolling and tripping on uneven ground. Many develop high arches or hammertoes that make some shoes uncomfortable. Braces or supportive shoes can ease strain and prevent falls.
Hand and grip
Over time, hand muscles can weaken, making tasks like opening jars or buttoning shirts harder. Fine finger movements may slow or feel clumsy. Occupational therapy often helps maintain dexterity.
Sensation changes
Numbness or reduced feeling in toes and fingers can make it hard to sense temperature or small injuries. Some feel tingling or burning, while others notice a “sock-like” loss of sensation. Not everyone with CMT1A has strong sensory symptoms.
Balance and fatigue
Unsteady footing is common, especially in the dark or on soft ground. Legs may tire quickly with walking or stairs, and cramps can show up after activity. Targeted strengthening and pacing strategies can reduce day-to-day fatigue.
Progression over time
Symptoms usually start in childhood or the teens but can begin later. The balance of symptoms can shift over time. People often adapt with supports at school, work, or home as needs change.
What genetics can tell you about symptoms
In CMT1A, a duplicated PMP22 gene makes too much myelin protein, which weakens the nerve insulation and slows signals to muscles. This often leads to foot drop, high arches, weak ankles and hands, numbness or tingling, and slower reflexes starting in childhood or teens.
Causes and risk factors
Charcot-Marie-Tooth disease type 1A is caused by an extra copy of the PMP22 gene that damages the insulating coating on peripheral nerves.
It often runs in families, and a new gene change can also appear for the first time.
Family history is the main risk, and an affected parent can pass it to a child.
Genes set the stage, but environment and lifestyle often decide how the story unfolds.
Certain medicines that harm nerves, repeated ankle injuries, diabetes, and heavy alcohol use can worsen nerve damage and may shift when early symptoms of Charcot-Marie-Tooth disease type 1A appear.
Environmental and biological risk factors
Here are the environmental and biological factors linked to how Charcot-Marie-Tooth disease type 1A (CMT1A) starts. Doctors often group risks into internal (biological) and external (environmental). These factors speak to the chance of CMT1A occurring; they don’t predict early symptoms of Charcot-Marie-Tooth disease type 1A.
The chromosome 17 region around the PMP22 gene contains repeated DNA segments that can misalign during egg or sperm formation. This biological setup increases the chance of a spontaneous duplication that leads to Charcot-Marie-Tooth disease type 1A. It reflects how the region is built, not anything under a parent’s control.
Many new duplications arise during sperm development. This means the change often starts in the father’s reproductive cells even when he is completely healthy. A consistent link with father’s age has not been clearly demonstrated.
No common environmental exposure has been proven to cause the specific PMP22 duplication. High-dose ionizing radiation can raise mutation rates in reproductive cells in general, but typical day-to-day exposures have not been tied to this duplication.
Genetic risk factors
Charcot-Marie-Tooth disease type 1A (CMT1A) is driven by a specific genetic change that affects the insulating covering of peripheral nerves. Most people with CMT1A carry an extra copy of a gene called PMP22, which often leads to signs in childhood or the teen years; recognizing early symptoms of Charcot-Marie-Tooth disease type 1A can help families seek care sooner. People with the same risk factor can have very different experiences.
PMP22 duplication: An extra copy of the PMP22 gene is the hallmark genetic cause of Charcot-Marie-Tooth disease type 1A. The added PMP22 upsets the myelin (nerve insulation) and slows nerve signals.
Autosomal dominant: This condition follows an autosomal dominant pattern. If a parent has the duplication, each child has a 50% (1 in 2) chance to inherit it. Females and males are affected at similar rates.
De novo cases: Sometimes the PMP22 duplication appears for the first time in a child. In these de novo cases, neither parent carries the change. The chance for future siblings to be affected is usually low.
Family history: A known family history of CMT1A increases the likelihood you carry the same PMP22 duplication. Patterns across generations often show parent-to-child transmission.
Likelihood of symptoms: Most people who carry the duplication eventually develop signs, often in childhood or adolescence. Some notice changes later, and severity can range from mild to more limiting.
Genetic modifiers: Differences in other genes can influence how severe the condition becomes and when it starts. This helps explain why symptoms can vary widely even within the same family. Research is ongoing to identify these modifiers.
PMP22 testing: A DNA test that checks for PMP22 duplication can confirm the genetic cause of CMT1A. Confirming the specific change in one family member allows targeted testing for relatives at risk. Early knowledge can guide monitoring and support.
Across populations: This condition affects people of all ethnic backgrounds worldwide. Because PMP22 sits on a non-sex chromosome, risks are similar for females and males.
Lifestyle risk factors
Lifestyle habits do not cause Charcot-marie-tooth disease type 1a, but they can shape how symptoms progress, how well you function day to day, and the risk of complications. Understanding how lifestyle affects Charcot-marie-tooth disease type 1a helps you make choices that protect nerves, muscles, and joints. Below are practical areas where habits can either help or hinder outcomes, focusing on lifestyle risk factors for Charcot-marie-tooth disease type 1a.
Regular low‑impact activity (like swimming, cycling, or brisk walking) helps maintain muscle strength, joint range, and balance in CMT1A. It may reduce fatigue and improve gait stability.
Pushing weak distal muscles to exhaustion can trigger cramps, tendon irritation, and temporary loss of function in CMT1A. Pacing activity and building rest breaks help prevent overuse injuries.
Excess body weight increases load on weakened ankles and intrinsic foot muscles, worsening pain, instability, and fall risk. Gradual weight loss can ease joint stress and improve endurance.
Supportive, wide‑toe, firm‑heel shoes and consistent orthotic use reduce ankle rolling, toe clawing, and skin breakdown in CMT1A. Unsupportive or high‑heeled shoes raise the risk of sprains and falls.
Risk prevention
For Charcot-Marie-Tooth disease type 1A (CMT1A), you can’t prevent the condition itself, but you can lower the chance of complications and protect day‑to‑day function. Prevention is about lowering risk, not eliminating it completely. The most helpful steps aim to maintain strength and balance, protect the feet, and avoid injuries or nerve pressure. Regular follow‑up and a few steady habits often make the biggest difference over time.
Schedule routine visits with a neuromuscular team to track strength, balance, and foot shape. Early adjustments in CMT1A can protect mobility and reduce setbacks.
Gentle strengthening, balance work, and stretching help keep muscles active and tendons flexible. A therapist can tailor safe exercises for Charcot-Marie-Tooth disease type 1A.
Choose low‑impact options like swimming, cycling, or brisk walking. Regular, moderate sessions support endurance without overtaxing weaker muscles.
Ankle‑foot orthoses and supportive shoes improve stability and reduce trips. Proper fit can prevent falls and pressure points in CMT1A.
Transmission
Charcot-Marie-Tooth disease type 1A (CMT1A) is not infectious and cannot be caught or spread through contact; it is inherited. Most often, a parent with CMT1A carries one changed copy of a gene and has a 50% chance with each pregnancy of passing it on; this pattern is known medically as autosomal dominant inheritance. In some families, CMT1A appears for the first time because of a new genetic change, so there may be no earlier family history. The genetic transmission of Charcot-Marie-Tooth disease type 1A can be unpredictable in severity—some relatives have mild symptoms while others are more affected—even though the chance of inheritance is the same. If you’re wondering how Charcot-Marie-Tooth disease type 1A is inherited in your family, a genetics professional can help map out your specific risks.
When to test your genes
Test your genes if you have slowly progressive foot weakness, high arches, or frequent ankle sprains—especially if close relatives have similar symptoms or a known CMT1A diagnosis. Consider testing before family planning or when choosing therapies like orthotics, surgery, or rehabilitation. Early confirmation guides monitoring, prevents harmful treatments, and connects you to supportive care.
Diagnosis
For many, the first step comes when everyday activities start feeling harder—tripping over toes, tiring quickly on stairs, or noticing shoes wear out at the fronts. Doctors look for a consistent pattern and then confirm it with tests. Some diagnoses are clear after a single visit, while others take more time. Charcot-marie-tooth disease type 1a is typically confirmed with a combination of nerve studies and genetic testing.
Providers check muscle strength, reflexes, and sensation, paying close attention to the feet and lower legs. Common findings include weaker ankle movement, decreased reflexes, and high arches or hammer toes.
A detailed family and health history can help reveal a pattern that suggests an inherited nerve condition. Because CMT1A is often autosomal dominant, clues may be present across generations, though severity can vary widely.
Nerve conduction studies measure how fast signals travel along nerves and often show slowed speeds consistent with demyelination. This helps separate CMT1A from axonal neuropathies and from acquired causes like diabetes or inflammation.
Electromyography can show how muscles respond to nerve signals and may reveal chronic changes from long‑standing nerve damage. EMG results complement nerve conduction studies when the picture is unclear.
Stages of Charcot-marie-tooth disease type 1a
Charcot-Marie-Tooth disease type 1A does not have defined progression stages. It usually changes slowly over many years and looks different from one person to the next, so care teams describe current abilities and test findings rather than placing people into set stages. Different tests may be suggested to help confirm the diagnosis and understand how it affects movement and sensation, including a neurological exam, nerve conduction studies, and genetic testing for the common gene change. Doctors typically monitor CMT1A over time by checking strength, feeling, balance, walking and hand tasks, documenting early symptoms of Charcot-Marie-Tooth disease type 1A such as ankle weakness or frequent tripping, and updating braces or therapy plans as needed.
Outlook and prognosis
Daily routines often adapt as Charcot-Marie-Tooth disease type 1A (CMT1A) changes strength and balance over the years—stairs may take longer, shoes may need extra support, and fatigue can shape how long errands last. The outlook is not the same for everyone, but most people with CMT1A have a normal life span. Weakness in the lower legs and feet usually shows up first and progresses slowly; for many, hand weakness appears later. Falls, ankle sprains, and foot deformities can add to disability, yet braces, physical therapy, and tailored footwear often steady walking and protect joints.
Understanding the prognosis can guide planning and help you spot early symptoms of CMT1A that benefit from prompt care, like increasing tripping, new foot drop, or hand cramps affecting buttons or keys. In medical terms, the long-term outlook is often shaped by both genetics and lifestyle, including activity level, joint protection, and avoiding nerve-toxic medications. Some people experience mild, steady symptoms for decades, while others notice quicker changes during growth spurts, pregnancy, or midlife; severe, sudden worsening is uncommon and should prompt a medical review. Breathing or swallowing problems are rare in CMT1A, and life-threatening complications are unusual.
With ongoing care, many people maintain work, family life, and hobbies, though adaptations—bracing, energy pacing, and home safety tweaks—make a difference. Looking at the long-term picture can be helpful. Talk with your doctor about what your personal outlook might look like, including how to track progression, reduce fall risk, and decide when to consider orthotics or hand therapy. Genetic testing can sometimes provide more insight into prognosis when there’s uncertainty about the specific subtype or family patterns.
Long-term effects
Charcot-Marie-Tooth disease type 1A usually progresses slowly over many years, mainly affecting strength and sensation in the feet, legs, and later the hands. Long-term effects vary widely, and changes can look different even within the same family. For many, day-to-day impact shows up as tired legs, unsteady walking on uneven ground, and hand tasks becoming more effortful. Early symptoms of Charcot-Marie-Tooth disease type 1A often start in the teens or young adulthood and tend to evolve into the long-term pattern described below.
Weakness often starts in the lower legs and feet, then may involve the hands. This can lead to foot drop, tripping, and difficulty running or climbing stairs. The course is typically slow over decades.
High arches and curled toes can gradually develop. These changes may make shoes uncomfortable and worsen ankle instability. They can increase the tendency to trip or sprain an ankle.
Reduced sensation in the feet and weaker ankle muscles make balance harder, especially in the dark or on uneven ground. Falls and ankle sprains can become more frequent over time. People may feel less confident walking on rough surfaces.
Grip can weaken and fine finger control can slow. Buttoning, writing, or opening jars may take more time. Hand cramps can occur with repeated tasks.
How is it to live with Charcot-marie-tooth disease type 1a?
Living with Charcot-Marie-Tooth disease type 1A often means planning around gradual muscle weakness and sensory loss in the feet and lower legs, and sometimes the hands. Daily life may involve choosing supportive footwear or braces, pacing activities to manage fatigue, and using hand grips or adaptive tools for fine tasks, while staying active with tailored physical therapy to protect mobility. Many find that open communication helps family, friends, and coworkers understand why you might walk more slowly, trip more easily, or need extra time for tasks. With consistent care, practical adaptations, and encouragement from those around you, people can work, study, travel, and build routines that keep independence and confidence at the center.
Treatment and drugs
Charcot‑Marie‑Tooth disease type 1A (CMT1A) is managed by easing symptoms, protecting function, and preventing complications, since no approved treatment can reverse the underlying nerve damage yet. Care usually centers on physical and occupational therapy to keep muscles strong and flexible, custom ankle‑foot orthoses or shoe inserts to improve balance and reduce tripping, and sometimes orthopedic surgery for severe foot deformities. Pain from muscle cramps or nerve pain can be treated with over‑the‑counter pain relievers or prescription medicines such as medications used for nerve pain; a doctor may also suggest magnesium, stretching, or night splints for cramps. Treatment plans often combine several approaches, and your doctor may review medications to avoid drugs known to worsen CMT (for example, certain chemotherapy agents). Supportive care can make a real difference in how you feel day to day, so regular follow‑up, fall‑prevention tips, and addressing fatigue, mood, and sleep are important parts of CMT1A care.
Non-drug treatment
Living with Charcot-Marie-Tooth disease type 1A often means adapting how you move, balance, and use your hands and feet in daily life. Alongside medicines, non-drug therapies can help you stay active, reduce falls, and protect joint health over time. Many people benefit most from a mix of approaches tailored to their goals and symptoms. Plans usually adjust over the years as needs change.
Gentle stretching and targeted strengthening help maintain joint motion and support weak ankle and foot muscles. Starting when early symptoms of Charcot-Marie-Tooth disease type 1A appear may help maintain mobility. A therapist can update your plan as needs change.
Exercises that train core, hips, and ankles can improve stability and reduce falls. Balance drills—like supported single-leg stands—are often built in. Programs are adjusted to avoid overworking weakened muscles.
Hand and wrist training can improve grip, dexterity, and endurance for writing, zippers, and cooking. Therapists suggest energy-saving ways to pace tasks. Adaptive tools can make daily activities safer and easier.
Lightweight braces help lift the toes and steady the ankle to reduce tripping. They can improve walking efficiency and lessen fatigue. Your team can fine-tune fit and stiffness as strength changes.
Your genes may have an impact on how drugs work for you
Medicines used in Charcot‑Marie‑Tooth disease type 1A can work differently depending on your genes, which affect drug processing and sensitivity to side effects. Genetic testing may guide safer choices and dosing, especially for medications that can worsen neuropathy.
Pharmacological treatments
There’s no single medicine that cures Charcot-Marie-Tooth disease type 1A, so drugs are used to ease symptoms like nerve pain, muscle cramps, or tremor. Not everyone responds to the same medication in the same way. Doctors usually start with well‑tolerated options and adjust based on relief, side effects, and your daily goals.
These calm overactive nerve signals and can reduce burning, shooting, or tingling pain. Neuropathic pain can be among the early symptoms of Charcot-Marie-Tooth disease type 1A. Drowsiness and dizziness are common at first.
These SNRIs help nerve pain and may also support mood and sleep. They can be a good alternative if gabapentin or pregabalin aren’t enough. Nausea, dry mouth, or sweating may occur.
Low doses at night can ease nerve pain and improve sleep quality. Dosing may be increased or lowered gradually to balance pain control with side effects like dry mouth or morning grogginess.
Lidocaine 5% patches or capsaicin cream can target small, focal pain areas without whole‑body side effects. They can be layered with oral medicines if needed. Skin irritation is the most common issue.
Genetic influences
In most people, Charcot-marie-tooth disease type 1a (also called CMT1A) is caused by an extra copy of a gene called PMP22. This extra copy leads to too much of a protein that helps insulate nerves, which can slow or disrupt the signals traveling to the feet, legs, hands, and arms. Even with the same gene change, people can have different ages when symptoms start and different levels of weakness or numbness. CMT1A typically follows what’s known medically as an autosomal dominant pattern—one altered copy is enough to cause the condition, and each child has a 50% chance of inheriting it. In some families there’s no prior history because the PMP22 change happens for the first time in the egg or sperm. Genetic testing can look for the extra PMP22 copy to confirm the diagnosis and guide who else in the family might benefit from testing or early support. Genes shape the risk and course, but they don’t fully predict when early symptoms of Charcot-marie-tooth disease type 1a will appear, so regular follow-up is still important.
Is Charcot-marie-tooth disease type 1a genetic?
Genetics are central in Charcot‑Marie‑Tooth disease type 1A. Most cases result from a PMP22 gene duplication, inherited in an autosomal dominant pattern, though new (de novo) changes occur. Variations can influence age at onset, symptom severity, and progression.
Pharmacogenetics—how genetics influence drug effects
The specific gene change in CMT1A—the extra copy of the PMP22 gene—doesn’t usually change how your liver breaks down most medicines, but it can make nerves more sensitive to drugs that harm them. Because of that vulnerability, doctors generally avoid certain chemotherapy that is strongly nerve‑toxic (for example, vincristine) or use alternatives and close monitoring if those treatments are unavoidable. Day to day, symptom care may include pain relievers, medicines for nerve pain that were originally made for depression or seizures, and drugs for cramps or sleep; your response to some of these can depend on your own drug‑metabolism genes. Alongside your medical history and current medicines, genetic testing may help pick or dose options such as codeine or tramadol, and can guide dosing for some tricyclic antidepressants used for nerve pain. For other common medicines, including some anti‑inflammatory pain relievers, gene results sometimes inform dose to reduce side effects, but treatment still needs to be tailored to your age, other conditions, and potential drug interactions. If you’re weighing medications for pain, cramps, or fatigue in Charcot-marie-tooth disease type 1a, ask whether any drug–gene testing or known nerve‑toxic risks should be considered before starting treatment.
Interactions with other conditions
Living with Charcot-Marie-Tooth disease type 1A can feel more complicated when another condition affects the nerves too. Diabetes, low thyroid function, heavy alcohol use, or a lack of vitamin B12 can all irritate nerves and may exacerbate (make worse) numbness, burning pain, or balance trouble in CMT1A. Some medicines are also nerve‑toxic; the chemotherapy drug vincristine is well known to cause severe worsening in people with CMT1A, and other chemo agents or long courses of certain antibiotics that affect nerves should be reviewed carefully with your care team. Doctors call it a “comorbidity” when two conditions occur together, and in day‑to‑day life this can make it harder to tell whether changes are due to CMT1A or something new.
Entrapment problems like carpal tunnel syndrome are more common in CMT1A and can mimic a flare, so targeted treatment for the trapped nerve may help even if the underlying CMT1A remains. Because early symptoms of Charcot-Marie-Tooth disease type 1A can overlap with diabetic neuropathy, regular foot checks and blood sugar management are especially important when both are present. During surgery or long procedures, careful positioning and padding to avoid prolonged pressure on nerves can reduce the risk of additional weakness or numbness afterward. Interactions can look very different from person to person, so bring an up‑to‑date medication list to each visit and ask your clinicians to coordinate care if multiple specialists are involved.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Families and communities once noticed patterns of unsteady walking, frequent ankle sprains, and high-arched feet that showed up across generations. A grandparent might have had thin calves and needed sturdy shoes; a teenager later developed the same “inward” ankles and tripped on uneven ground. These lived observations came long before tests could explain why.
Throughout history, people have described slowly progressive weakness in the lower legs and feet, sometimes later in the hands. Early doctors grouped these findings under broad labels for nerve-related weakness. From early theories to modern research, the story of Charcot‑Marie‑Tooth disease type 1A (CMT1A) traces how careful observation guided science toward the nerves themselves.
First described in the medical literature as a hereditary neuropathy in the late 1800s, the condition carried the names of three physicians—Charcot, Marie, and Tooth—who linked family histories to a shared pattern of muscle wasting and sensory loss. Initially understood only through symptoms, later nerve studies showed that signals traveled more slowly along the affected nerves, pointing to changes in the protective myelin coating.
With the rise of molecular genetics in the late 20th century, researchers discovered that most people with this form have an extra copy (duplication) of a gene called PMP22. That finding tied the clinical picture to a clear biological cause: too much PMP22 disrupts myelin, much like a frayed layer around a wire that makes electrical signals weaker and slower. Advances in genetics also explained why CMT1A often appears in multiple relatives and why severity can vary even within the same family.
Over time, descriptions became more precise. What was once a single broad diagnosis was divided into types based on how nerves are affected and which gene changes are involved. CMT1A emerged as the most common subtype worldwide. This shift allowed earlier recognition—sometimes from the first hints of foot deformities in childhood—and more focused care such as bracing, physiotherapy, and fall‑prevention strategies.
In recent decades, awareness has grown about the everyday impact of CMT1A, from walking endurance to hand tasks that require fine control. Genetic testing moved from research settings into routine clinics, helping confirm the diagnosis without invasive procedures. At the same time, registries and international collaborations began tracking long‑term outcomes, setting the stage for treatment trials.
Knowing the condition’s history helps explain today’s approach: listen closely to family stories, examine how the nerves conduct signals, and use targeted genetic testing to confirm CMT1A. Each step—from bedside observations to gene discovery—built the foundation for current care and for future therapies aimed at correcting the underlying biology.